GB5121

Gossamer Bio announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events
Investing.com
Mon, 04/3/23 - 10:59 pm
Gossamer Bio
GB5121
Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile
Fierce Biotech
Sun, 03/19/23 - 01:43 pm
Gossamer Bio
clinical trials
GB5121
lymphoma